Cellebrite DI LtdCLBT
Price$11.14Intrinsic value$12.9216% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $475.7M+18.6% YoYTTM through 31 Dec 2025
Net Income $78.3MTTM through 31 Dec 2025
Free Cash Flow $160.3MTTM through 31 Dec 2025

Margins

Current
Gross Margin84.2%
EBITDA Margin16.5%
Operating Margin14.0%
Net Margin16.5%

Returns

16.2%ROE
8.3%ROA

Balance Sheet Health

Current Ratio1.56x
Cash & Equivalents$124.5M

Quality Metrics

Altman Z-Score4.74
Piotroski F-Score4 / 9
FCF Margin33.7%
Rule of 4050.7
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $475.7M
Diluted EPS$0.31TTM
'19'20'21'22'23'24'25
FY2025: $0.31

Dividend

No dividend

Capital Allocation

R&D Spend$113.9M
Capex Intensity2.8%

Segment Performance

No segment data available.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.